Researchers testing the effectiveness of Pfizer's vaccine say it could continue fending off the coronavirus for years. The news comes just hours after Pfizer officials revealed the vaccine it developed with BioNTech is effective for more than six months in many cases. “The information coming from Pfizer-BioNTech is good news with evidence that those enrolled in the clinical trials last year are still protected,” says Dr. Peter Hotez, dean of Baylor College’s school of tropical medicine. “So we know that immunity will not be short-lived.” The longevity means the vaccine should have no trouble taking on coronavirus variants, says University of Pennsylvania specialist Dr. Scott Hensley. “The vaccine elicits such high levels of antibodies that, even when confronted with a variant, there’s still meaningful protection,” he says.